Jes Thorn Clausen

This inventor holds 10 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Novo Nordisk A/s. Active years: 2012-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jes Thorn Clausen. Retrieved from https://idiyas.com/inventor/jes-thorn-clausen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 8)

% Patents Active = 70.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Høng, DK (2012)
Hoeng, DK (2013 - 2019)

Company Filing History:

10 out of 1,802

Novo Nordisk A/s

patents

Years Active: 2012-2019

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10457743 - Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity (2019-10-29),

2. 10106606 - Targeting tissue factor to activated platelets (2018-10-23),

3. 9574011 - Antibodies against tissue factor pathway inhibitor (2017-02-21),

4. 9260518 - Antibodies that are capable of specifically binding tissue factor pathway inhibitor (2016-02-16),

5. 9228022 - Antibodies that are capable of specifically binding tissue factor pathway inhibitor (2016-01-05),

6. 9062115 - Therapeutic factor VIII antibodies (2015-06-23),

7. 8652471 - Methods of treating coagulopathies using antibodies against tissue factor pathway inhibitor (2014-02-18),

8. 8618263 - Antibodies against tissue factor pathway inhibitor (TFPI) (2013-12-31),

9. 8361469 - Antibodies against tissue factor pathway inhibitor (2013-01-29),

10. 8287861 - Anti-human interleukin-20 antibodies (2012-10-16),

Title: Jes Thorn Clausen: Innovator in Coagulation Research

Introduction

Jes Thorn Clausen is a prominent inventor based in Hoeng, Denmark. He has made significant contributions to the field of coagulation research, holding a total of 10 patents. His work focuses on developing innovative solutions for treating coagulopathies, particularly in patients with hemophilia.

Latest Patents

One of his latest patents is titled "Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity." This invention relates to an antibody that specifically binds to an epitope in the N-terminal part of tissue factor pathway inhibitor (TFPI). The antibody may neutralize TFPI inhibition of the TF/FVIIa complex, even in the presence of elevated levels of TFPI. Such antibodies have potential utility in treating subjects with coagulopathy, including those with hemophilia A or B, with or without inhibitors. Another significant patent is "Targeting tissue factor to activated platelets." This invention involves procoagulant fusion proteins, polynucleotides encoding these fusion proteins, and cells that express them. The fusion proteins are intended for use as a medicament for individuals with coagulopathy, such as hemophilia A and B.

Career Highlights

Jes Thorn Clausen is associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk has allowed him to focus on innovative research and development in the field of coagulation.

Collaborations

He has collaborated with notable colleagues, including Ida Hilden and Berit Olsen Krogh, contributing to advancements in coagulation therapies.

Conclusion

Jes Thorn Clausen is a key figure in the field of coagulation research, with a strong portfolio of patents that aim to improve treatment options for patients with coagulopathies. His innovative work continues to have a significant impact on medical science.

Profile summary based on public USPTO records.